MAFD8
MCID: MJR022
MIFTS: 37

Major Affective Disorder 8 (MAFD8)

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Affective Disorder 8

MalaCards integrated aliases for Major Affective Disorder 8:

Name: Major Affective Disorder 8 57 13 70
Major Affective Disorder-8, Susceptibility to 57
Bipolar Affective Disorder 57
Major Affective Disorder-8 57
Bipolar Disorder 70
Mafd8 57

Classifications:



External Ids:

OMIM® 57 612357
MedGen 41 C2700439
UMLS 70 C0005586 C2700439

Summaries for Major Affective Disorder 8

MalaCards based summary : Major Affective Disorder 8, also known as major affective disorder-8, susceptibility to, is related to major affective disorder 1 and bipolar disorder. An important gene associated with Major Affective Disorder 8 is MAFD8 (Major Affective Disorder-8, Susceptibility To). The drugs Eleuthero and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex.

More information from OMIM: 612357

Related Diseases for Major Affective Disorder 8

Diseases in the Major Affective Disorder 1 family:

Major Affective Disorder 2 Major Affective Disorder 3
Major Affective Disorder 4 Major Affective Disorder 5
Major Affective Disorder 6 Major Affective Disorder 8
Major Affective Disorder 7 Major Affective Disorder 9

Diseases related to Major Affective Disorder 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 major affective disorder 1 11.9
2 bipolar disorder 11.7
3 major affective disorder 5 11.6
4 major affective disorder 6 11.6
5 major affective disorder 9 11.5
6 major affective disorder 2 11.4
7 major affective disorder 3 11.4
8 major affective disorder 4 11.4
9 major affective disorder 7 11.4
10 mood disorder 10.8
11 schizophrenia 10.8
12 depression 10.7
13 endogenous depression 10.7
14 mental depression 10.7
15 bipolar i disorder 10.6
16 major depressive disorder 10.6
17 psychotic disorder 10.5
18 personality disorder 10.5
19 obsessive-compulsive disorder 10.5
20 schizoaffective disorder 10.5
21 alcohol dependence 10.4
22 tardive dyskinesia 10.4
23 hypothyroidism 10.4
24 substance abuse 10.4
25 borderline personality disorder 10.4
26 huntington disease 10.3
27 attention deficit-hyperactivity disorder 10.3
28 parkinsonism 10.3
29 cyclothymic disorder 10.3
30 anxiety 10.3
31 hydrocephalus 10.3
32 dementia 10.3
33 thalassemia 10.3
34 head injury 10.3
35 schizophrenia 1 10.2
36 frontotemporal dementia 10.2
37 mental health wellness 1 10.2
38 mental health wellness 2 10.2
39 alacrima, achalasia, and mental retardation syndrome 10.2
40 exanthem 10.2
41 physical disorder 10.2
42 thalassemia minor 10.2
43 movement disease 10.2
44 panic disorder 10.2
45 severe combined immunodeficiency 10.2
46 adenoma 10.2
47 hyperthyroidism 10.2
48 learning disability 10.2
49 substance dependence 10.2
50 darier-white disease 10.1

Graphical network of the top 20 diseases related to Major Affective Disorder 8:



Diseases related to Major Affective Disorder 8

Symptoms & Phenotypes for Major Affective Disorder 8

Clinical features from OMIM®:

612357 (Updated 20-May-2021)

Drugs & Therapeutics for Major Affective Disorder 8

Drugs for Major Affective Disorder 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 423)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eleuthero Approved, Experimental Phase 4
2
Coal tar Approved Phase 4 8007-45-2
3
Clozapine Approved Phase 4 5786-21-0 2818
4
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
5
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7
Norepinephrine Approved Phase 4 51-41-2 439260
8
Donepezil Approved Phase 4 120014-06-4 3152
9
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
10
Loxapine Approved Phase 4 1977-10-2 3964
11
Sertraline Approved Phase 4 79617-96-2 68617
12
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
13
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
14
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
15
Galantamine Approved Phase 4 357-70-0 9651
16
Memantine Approved, Investigational Phase 4 19982-08-2 4054
17
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
18
Topiramate Approved Phase 4 97240-79-4 5284627
19
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
20
Oxcarbazepine Approved Phase 4 28721-07-5 34312
21
Iloperidone Approved Phase 4 133454-47-4 71360
22
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
23
Ondansetron Approved Phase 4 99614-02-5 4595
24
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
25
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
26
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
27
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
28
Nortriptyline Approved Phase 4 72-69-5 4543
29
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
30
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
31
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
32
Levetiracetam Approved Phase 4 102767-28-2 441341
33
Methohexital Approved Phase 4 151-83-7 9034
34
Dipyridamole Approved Phase 4 58-32-2 3108
35
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
36
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
37
Metformin Approved Phase 4 657-24-9 14219 4091
38
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
39
Atorvastatin Approved Phase 4 134523-00-5 60823
40
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
41
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
42
Nicotine Approved Phase 4 54-11-5 942 89594
43
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
44
Racepinephrine Approved Phase 4 329-65-7 838
45
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
46
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
47
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
48
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
49
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
50
Simvastatin Approved Phase 4 79902-63-9 54454

Interventional clinical trials:

(show top 50) (show all 1273)
# Name Status NCT ID Phase Drugs
1 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
2 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
3 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
4 A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder Unknown status NCT02562287 Phase 4 Clozapine;Risperidone;Olanzapine;Quetiapine
5 Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder Unknown status NCT02478788 Phase 4 mixed amphetamine salts-extended release (MAS-XR);Placebo
6 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
7 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
8 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
9 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
10 A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression Unknown status NCT02719392 Phase 4 Minocycline
11 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
12 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
13 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
14 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
15 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
16 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
17 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
18 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
19 Acute Antidepressant Therapy in Bipolar II Major Depression Completed NCT00641927 Phase 4 Venlafaxine;Lithium Carbonate
20 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
21 A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania Completed NCT01191918 Phase 4 Donepezil and Lithium;Placebo plus Lithium
22 Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking Completed NCT00621777 Phase 4 Varenicline;Placebo
23 Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients Completed NCT02644577 Phase 4 Metformin
24 A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting Completed NCT02525991 Phase 4
25 A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide Completed NCT01416220 Phase 4 Lithium;Paroxetine
26 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
27 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
28 Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181987 Phase 4 methylphenidate HCl (Concerta)
29 Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder Completed NCT00181935 Phase 4 risperidone (Risperdal);olanzapine (Zyprexa)
30 Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder Completed NCT00181922 Phase 4 ziprasidone (Geodon)
31 Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181779 Phase 4 aripiprazole (Abilify)
32 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
33 Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder Completed NCT00181883 Phase 4 quetiapine
34 Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181870 Phase 4 carbamazepine ER (Equetro)
35 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
36 Open-Label Study of Divalproex Sodium Extended Release for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181727 Phase 4 divalproex sodium extended release
37 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine
38 Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics Completed NCT01811160 Phase 4 Melatonin;Placebo
39 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
40 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
41 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
42 Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium;Divalproex;Lamotrigine;Quetiapine
43 The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder Completed NCT00741598 Phase 4 Galantamine-ER;Galantamine placebo
44 Ziprasidone in Pediatric Bipolar Disorder: a 6-week, Open-label Comparison of Rapid vs. Slow Dose Titration Completed NCT00622739 Phase 4 Ziprasidone;Ziprasidone
45 Cognitive Enhancement in Bipolar Disorder Completed NCT00597896 Phase 4 pramipexole
46 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Completed NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
47 A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder. Completed NCT00552760 Phase 4 Ramelteon;Placebo
48 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
49 Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change Completed NCT03408873 Phase 4 Abilify Maintena
50 Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder Completed NCT01293825 Phase 4 ziprasidone

Search NIH Clinical Center for Major Affective Disorder 8

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Genetic Tests for Major Affective Disorder 8

Anatomical Context for Major Affective Disorder 8

MalaCards organs/tissues related to Major Affective Disorder 8:

40
Brain, Cortex, Prefrontal Cortex, Amygdala, Cingulate Cortex, Thyroid, Eye

Publications for Major Affective Disorder 8

Articles related to Major Affective Disorder 8:

(show top 50) (show all 27309)
# Title Authors PMID Year
1
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. 57 61
18711365 2008
2
Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. 61
33577882 2021
3
In Vitro and In Vivo Evidence on the Role of Mitochondrial Impairment as a Mechanism of Lithium-Induced Nephrotoxicity. 61
32712907 2021
4
Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes. 61
33411239 2021
5
Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. 61
33411248 2021
6
Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. 61
33515607 2021
7
Treatment effect variability in brain stimulation across psychiatric disorders: A meta-analysis of variance. 61
33482243 2021
8
Preventive effect of morning light exposure on relapse into depressive episode in bipolar disorder. 61
33587769 2021
9
Emotion regulation in pediatric bipolar disorder: A meta-analysis of published studies. 61
33639359 2021
10
Neuroprotective Effect of Intravitreal Single-Dose Lithium Chloride after Optic Nerve Injury in Rats. 61
32885675 2021
11
The case for prescribing PrEP in community mental health settings. 61
33493438 2021
12
Emotional and Behavioral Dysregulation in Severe Mental Illness. 61
33743948 2021
13
The role of brain barriers in the neurokinetics and pharmacodynamics of lithium. 61
33549730 2021
14
Validation of the Yale Food Addiction Scale 2.0 in Patients Seeking Bariatric Surgery. 61
33405178 2021
15
Using additive and relative hazards to quantify colorectal survival inequalities for patients with a severe psychiatric illness. 61
33239182 2021
16
Does maternal race or ethnicity modify the association between maternal psychiatric disorders and preterm birth? 61
33393465 2021
17
Patterns of Mental Health Care Before Initiation of Telemental Health Services. 61
33797510 2021
18
Internet of things issues related to psychiatry. 61
33797634 2021
19
Predictors of Prolonged Length of Stay in Suicidal Children Transferred to Psychiatric Facilities. 61
33782014 2021
20
How and Why Are Irritability and Depression Linked? 61
33743947 2021
21
25 Years of the International Bipolar Collaborative Network (BCN). 61
33811284 2021
22
Cancer Screening Among Adults With and Without Serious Mental Illness: A Mixed Methods Study. 61
33704103 2021
23
Gut microbiota-derived vitamins - underrated powers of a multipotent ally in psychiatric health and disease. 61
33428888 2021
24
Lived Experiences of a Sustained Mental Health Recovery Process Without Ongoing Medication Use. 61
32696208 2021
25
Using machine learning analyses of speech to classify levels of expressed emotion in parents of youth with mood disorders. 61
33549901 2021
26
Multimodal imaging improves brain age prediction and reveals distinct abnormalities in patients with psychiatric and neurological disorders. 61
33340180 2021
27
Trends in Trimorbidity Among Adults Experiencing Homelessness in Minnesota, 2000-2018. 61
33710099 2021
28
Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. 61
31397223 2021
29
Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders. 61
31712721 2021
30
Risk factors for natural cause mortality in a cohort of 1494 persons with serious mental illness. 61
33578064 2021
31
Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. 61
33595954 2021
32
Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. 61
33387333 2021
33
Performance on the Wechsler Adult Intelligence Scale (WAIS) in Japanese patients with bipolar and major depressive disorders in euthymic and depressed states. 61
33368739 2021
34
Olfactory Neuroepithelium Cells from Cannabis Users Display Alterations to the Cytoskeleton and to Markers of Adhesion, Proliferation and Apoptosis. 61
33237429 2021
35
Accelerated brain aging predicts impulsivity and symptom severity in depression. 61
33495545 2021
36
Use of social media and online dating among individuals with a history of affective disorder. 61
33054870 2021
37
A meta-study on transcription factor networks in the suicidal brain. 61
33548827 2021
38
Aripiprazole and lactation failure: The importance of shared decision making. A case report. 61
33796446 2021
39
Investigation of risk of dementia diagnosis and death in patients in older people's secondary care mental health services. 61
33113255 2021
40
EEG based Major Depressive disorder and Bipolar disorder detection using Neural Networks:A review. 61
33657466 2021
41
Clinical characteristics of bipolar disorders with postpartum depressive onset. 61
33347983 2021
42
Changes in Intrinsic Brain Connectivity in Family-Focused Therapy Versus Standard Psychoeducation Among Youths at High Risk for Bipolar Disorder. 61
32745598 2021
43
Analysis of functional MRI signal complexity based on permutation fuzzy entropy in bipolar disorder. 61
33657075 2021
44
Genetic neuroimaging of bipolar disorder: a systematic 2017-2020 update. 61
33492063 2021
45
The association between self-reported physical activity and objective measures of physical activity in participants with newly diagnosed bipolar disorder, unaffected relatives, and healthy individuals. 61
33779478 2021
46
The functional polymorphisms linked with interleukin-1β gene expression are associated with bipolar disorder. 61
33707400 2021
47
A nationwide population-based longitudinal study mapping psychiatric disorders during lifetime in siblings to patients with bipolar disorder. 61
33258104 2021
48
Manic morbidity and executive function impairment as determinants of long-term psychosocial dysfunction in bipolar disorder. 61
33792890 2021
49
Brain activation during verbal fluency task in type II bipolar disorder patients: a near-infrared spectroscopy study. 61
33545426 2021
50
Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder. 61
33618245 2021

Variations for Major Affective Disorder 8

Expression for Major Affective Disorder 8

Search GEO for disease gene expression data for Major Affective Disorder 8.

Pathways for Major Affective Disorder 8

GO Terms for Major Affective Disorder 8

Sources for Major Affective Disorder 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....